Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery.

Publication Type:

Journal Article


Journal of translational medicine, Volume 6, p.41 (2008)


2008, Antibodies, Antibody Development Core Facility, Basic Sciences Division, BIOTINYLATION, Case-Control Studies, Center-Authored Paper, Clinical Research Division, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry Core Facility, Fluorescent Antibody Technique, Indirect, GLYCOPROTEINS, Humans, Neoplasm Staging, Ovarian Neoplasms, Phosphatidylethanolamine Binding Protein, Proteomics Core Facility, Recombinant Proteins, Reproducibility of Results, Sensitivity and Specificity, Shared Resources, Solubility, Tumor Markers, Biological, von Willebrand Factor, Yeasts


Strategies to discover circulating protein markers of ovarian cancer are urgently needed. We developed a novel technology that permits us to isolate recombinant antibodies directed against the potential serum biomarkers, to facilitate the further development of affinity reagents necessary to construct diagnostic tests.